TY - JOUR
T1 - Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors
AU - Li, Yan
AU - Li, Xu
AU - Fan, Guangyu
AU - Fukushi, Jun ichi
AU - Matsumoto, Yoshihiro
AU - Iwamoto, Yukihide
AU - Zhu, Yue
N1 - Funding Information:
We thank Drs. M. Kuwano (Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Japan) for the pRc-p53 expression vector and F. van Valen (Department of Orthopaedics, University Hospital, Munster, Germany) for WE-68 and VH-64. This study was supported by National Natural Science Foundation of China (No. 30973021) and Basic Research Promotion Grant (No. 196) of Japan Orthopaedics and Traumatology Foundation, Inc.
PY - 2012/7/1
Y1 - 2012/7/1
N2 - The chromosomal translocation t(11;22)(q24;q12) yields the EWS-Fli1 fusion gene, which contributes to the development of Ewing Family Tumors (EFTs). Previous studies have shown the ability of EWS-Fli1 chimeric protein to silence p53 activity. Here we demonstrate that the introduction of EWS-Fli1 significantly inhibited p300-mediated acetylation of p53 at Lys-382 and depletion of EWS-Fli1 protein by small interfering RNAs (siRNA) in EFTs cells facilitated it in response to DNA damage. Furthermore, the deacetylation of p53 by EWS-Fli1 suppressed its transcriptional activity and enhanced mdm2-mediated p53 degradation. On the other hand, immunoprecipitation study shows that N-terminal region of EWS-Fli1 associated with histone deacetylase 1 (HDAC1) to forms a complex with p53.Knockdown of HDAC1, but not HDAC2 or HDAC3 protein restored the expression of p53 Lys-382 in EFTs cells. Overexpression of HDAC1 also significantly inhibited p53 transcriptional activity. Pharmacologic inhibitor of HDAC, trichostatin A (TSA) promoted p53-p300 interaction and recruitment of p53 Lys-382 to promoter regions of its target genes p21 and Puma, consequently inducing apoptosis and stabilizing the acetylation of p53 at Lys-382 together with the upregulation of p21 and Puma, which were impaired in EFTs cells after the knockdown of p53 expression. Our data indicate EWS-Fli1 might deacetylate p53 to inhibit its transcriptional function and protein stability via the recruitment of HDAC1. These results might elucidate a novel molecular mechanism about the abrogation of p53 pathway by EWS-Fli1 in EFTs pathogenesis.
AB - The chromosomal translocation t(11;22)(q24;q12) yields the EWS-Fli1 fusion gene, which contributes to the development of Ewing Family Tumors (EFTs). Previous studies have shown the ability of EWS-Fli1 chimeric protein to silence p53 activity. Here we demonstrate that the introduction of EWS-Fli1 significantly inhibited p300-mediated acetylation of p53 at Lys-382 and depletion of EWS-Fli1 protein by small interfering RNAs (siRNA) in EFTs cells facilitated it in response to DNA damage. Furthermore, the deacetylation of p53 by EWS-Fli1 suppressed its transcriptional activity and enhanced mdm2-mediated p53 degradation. On the other hand, immunoprecipitation study shows that N-terminal region of EWS-Fli1 associated with histone deacetylase 1 (HDAC1) to forms a complex with p53.Knockdown of HDAC1, but not HDAC2 or HDAC3 protein restored the expression of p53 Lys-382 in EFTs cells. Overexpression of HDAC1 also significantly inhibited p53 transcriptional activity. Pharmacologic inhibitor of HDAC, trichostatin A (TSA) promoted p53-p300 interaction and recruitment of p53 Lys-382 to promoter regions of its target genes p21 and Puma, consequently inducing apoptosis and stabilizing the acetylation of p53 at Lys-382 together with the upregulation of p21 and Puma, which were impaired in EFTs cells after the knockdown of p53 expression. Our data indicate EWS-Fli1 might deacetylate p53 to inhibit its transcriptional function and protein stability via the recruitment of HDAC1. These results might elucidate a novel molecular mechanism about the abrogation of p53 pathway by EWS-Fli1 in EFTs pathogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84862785899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862785899&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2012.01.018
DO - 10.1016/j.canlet.2012.01.018
M3 - Article
C2 - 22266186
AN - SCOPUS:84862785899
SN - 0304-3835
VL - 320
SP - 14
EP - 22
JO - Cancer Letters
JF - Cancer Letters
IS - 1
ER -